

Cover Story
FreeNews Analysis
By Matthew Bin Han Ong
Now that Joseph R. Biden Jr. is inaugurated and safely ensconced in the White House, cancer groups expect him to pick up where he left off as vice president four years ago—pursuing a sober and ambitious agenda for accelerating progress in cancer research.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Biden’s FY23 proposal cuts NCI funds by $199M, while boosting ARPA-H by $4B
- Trump et al. focus on NIH, cancer—and how peer review is done
- Fired NCI employee says Trump’s purge was baseless yet punitive
“I feel like I’ve been erased” - Bhattacharya provides calm answers to anxious questions at confirmation hearing
Trump nominee for NIH director calls for transparency, audits of indirect costs - Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president